The FDA has granted two Breakthrough Therapy Designations to telisotuzumab adizutecan (Temab-A, also known as ABBV-400), an ...
Legacy Healthcare, a biopharmaceutical company developing innovative botanical prescription drugs, today announced that the U ...
AbbVie (NYSE:ABBV) received two FDA Breakthrough Therapy Designations for its experimental cancer drug telisotuzumab ...
Therapeutic gene transfer to specific brain regions in animal models of Alzheimer's disease has uncovered multiple potential treatment approaches that deserve to be considered as candidates for ...
AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has granted two Breakthrough Therapy Designations (BTDs) for telisotuzumab adizutecan (Temab-A; ABBV-400) in ...
AbbVie announced that the U.S. Food and Drug Administration (FDA) has granted two Breakthrough Therapy Designations (BTDs) for telisotuzumab adizutecan (Temab-A; ABBV-400) in colorectal cancer (CRC) ...
Orchestra BioMed has announced that the FDA has granted Breakthrough Device Designation for its atrioventricular interval modulation (AVIM) therapy, aimed at treating over 7.7 million U.S. patients ...
A study evaluating a pioneering lentivirus (LV)-mediated gene therapy trial for classical Fabry disease showed promising results over five years, indicating a potential breakthrough in treatment for ...
The FDA will speed up their review of Enhertu for HR-positive, HER2-low/ultralow advanced breast cancer that cannot be removed via surgery. The Food and Drug Administration (FDA) granted a ...
AbbVie ( ABBV ), a biopharmaceutical company, announced that the U.S. FDA has granted two Breakthrough Therapy Designations for telisotuzumab adizutecan (Temab-A; ABBV-400) in colorectal cancer (CRC) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results